Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07008027 · ClinicalTrials.gov registry record
Real World Asparaginase Therapy Toxicity
A clinical trial, sponsored by St. Jude Children's Research Hospital.
- Not yet
- Registry status
- 200
- Enrollment target
NCT07008027: Clinical Trial study, sponsored by St. Jude Children's Research Hospital.
NCT07008027 is a clinical trial that has not yet begun recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07008027 has not yet begun recruiting, sponsored by St. Jude Children's Research Hospital.
- NOT YET RECRUITING
- Registry status
- 200 participants
- Enrollment target
Study Summary
This research study is being done to learn more about the short term and long term side effects of treatment with asparaginase drugs, which are commonly used in acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy) therapy.
Primary Outcome
The overall probability of on-therapy grade 3+ or 4+ toxicity will be estimated by the sample proportion along with the Normal approximation (Z-statistic) based 95% confidence interval.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-07 |
What is known before NCT07008027 opens enrollment
NCT07008027 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07008027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07008027 about?
NCT07008027 is a clinical study titled "Real World Asparaginase Therapy Toxicity". This research study is being done to learn more about the short term and long term side effects of treatment with asparaginase drugs, which are commonly used in acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy) therapy.
What is the current status of trial NCT07008027?
This trial is currently not yet recruiting. The enrollment target is 200 participants. The study started on 2026-07. Estimated completion is 2031-07.
Who is sponsoring clinical trial NCT07008027?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia